Authors

Panelists Johanna Bendell, MD, Sarah Cannon

Latest:

Dr. Ascierto on Choosing Combinations in Treatment of Melanoma

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how to choose between combination therapies in the treatment of patients with melanoma.

Paolo Ghia, MD

Latest:

Dr Ghia on Potential Future Roles for Ibrutinib Plus Venetoclax in CLL

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Parameswaran Hari, MD, MRCP

Latest:

Examining the Importance of the Institutional Perspectives in Cancer Webinars

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin

Latest:

Narsoplimab Trial Results

The panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.

Parminder Singh, MD

Latest:

Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder Cancer

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Partow Kebriaei, MD

Latest:

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Pascale Guitera, MD

Latest:

Dr. Guitera on the RADICAL Trial for Melanoma

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Pashtoon M. Kasi, MBBS, MD, MS

Latest:

Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRC

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

Pashtoon M. Kasi, MD, MS

Latest:

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS

Latest:

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Pasi A. Jänne, MD, PhD

Latest:

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

Pasi A. Janne, MD, PhD, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Harvard University

Pat W. Whitworth, MD

Latest:

Dr. Whitworth on Treating Breast Cancer With Chemo

Dr. Pat Whitworth, from the Vanderbilt University Medical Center, Discusses Chemotherapy for Breast Cancer

Pat Whitworth, MD

Latest:

Dr. Whitworth on the Importance of Additional HER2 Subtyping

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

Patrice Olson

Latest:

Biomarkers Predict Prognosis for Patients With mCRPC

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer

Patricia Ganz, MD

Latest:

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Patricia J. Goldsmith

Latest:

Patricia Goldsmith on Financial Stress Associated With Cancer Care

Patricia J. Goldsmith, chief executive officer, CancerCare, previews data of a CancerCare study highlighting some of the financial challenges associated with patients who have cancer.

Patricia LoRusso, DO

Latest:

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Patricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.

Patricia M. LoRusso, DO

Latest:

Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.